Evidence map›Paper›PMID 36968045›Full record

ReviewRSC advances2023

MXene-based composites against antibiotic-resistant bacteria: current trends and future perspectives.

Siavash Iravani, Rajender S Varma

Open access · goldAbstract readReview
In one paragraph

Review in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Electron Beam-Irradiated g-CGels (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. NHHeliyon · 2024
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Siavash IravaniFaculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences 81746-73461 Isfahan Iran siavashira@gmail.com.ORCID https://orcid.org/0000-0003-3985-7928
Rajender S VarmaInstitute for Nanomaterials, Advanced Technologies and Innovation (CxI), Technical University of Liberec (TUL) Studentská 1402/2 Liberec 1 461 17 Czech Republic.ORCID https://orcid.org/0000-0001-9731-6228
Isfahan University of Medical Sciences · IRTechnical University of Liberec · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Today, finding novel nanomaterial-based strategies to combat bacterial resistance is an important field of science. MXene-based composites have shown excellent antimicrobial potential owing to their fascinating properties such as excellent photothermal effects, highly active sites, large interlayer spacing, unique chemical structures, and hydrophilicity; they have great potential to damage the bacterial cells by rupturing the bacterial cell membranes, enhancing the permeability across the membrane, causing DNA damages, reducing the metabolic activity, and generating oxidative stress. After inserting into or attaching on the surface of pathogenic bacteria, these two-dimensional structures can cause bacterial membrane disruption and cell content leakage owing to their sharp edges. Remarkably, MXenes and their composites with excellent photothermal performance have been studied in photothermal antibacterial therapy to combat antibiotic-resistant bacteria and suppress chronic wound infections, thus providing new opportunities for multidrug-resistant bacteria-infected wound healing. But, details about the possible interactions between MXene-based nanosystems and bacterial cell membranes are rather scarce. Also, the mechanisms of photothermal antibacterial therapy as well as synergistic tactics including photothermal, photodynamic or chemo-photothermal therapy still need to be uncovered. This review endeavors to delineate critical issues pertaining to the application of MXene-based composites against antibiotic-resistant bacteria, focusing on their photocatalytic inactivation, physical damage, and photothermal antibacterial therapy.

Identifiers

PMID36968045
PMCPMC10038123
OpenAlexW4360910058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.